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Introduction
Since 2011, 10 new drug therapies have been approved for treatment of patients with stage IV metastatic melanoma and have dramatically improved outcomes. Many of these agents are being evaluated in trials for patients with earlier disease stages, and recent adjuvant trials demonstrated improvements in relapse-free survival (RFS) after surgery for stage III melanoma [1] [2] [3] . In analyses carried out for the 8th edition of the American Joint Committee on Cancer (AJCC) melanoma staging system [4] , 5-year melanoma-specific survival (MSS) for stage III patients was as low as 32% (stage IIID), underscoring the critical need to improve their outcomes.
The clinical successes of targeted and immune-checkpoint therapies in patients with advanced disease have also prompted an assessment of their efficacy in the neoadjuvant setting. Neoadjuvant cytotoxic and/or targeted therapy is currently accepted standard of care for many patients with breast [5] , colorectal [6] , and gastro-esophageal [7] cancers and offers several advantages. First, it provides a unique window to gauge antitumor efficacy of agents via pathologic examination of the definitive resection specimen. Whereas persistence of viable tumor after therapy might indicate the need to alter or explore novel treatments in the adjuvant setting, tumor eradication might lend support to continuation or even cessation of the current therapy. Second, neoadjuvant therapy potentially eradicates clinically occult disease, preventing or delaying disease relapse. Finally, it has the potential to shrink unresectable tumor to enable surgery, which may additionally be less morbid [8] .
A recent randomized phase II clinical trial compared safety and efficacy of neoadjuvant and adjuvant dabrafenib and trametinib targeted therapy to standard-of-care (SOC) surgery in patients with surgically resectable stage III or oligometastatic stage IV melanoma. Patients who received neoadjuvant therapy had a >60-fold reduced risk of relapse after surgery compared with those who underwent SOC surgery [9] . Similarly, in a phase II study of 35 patients with resectable stage III or oligometastatic stage IV metastatic melanoma, 17 (49%) patients who received dabrafenib and trametinib had a complete pathologic response (pCR), and no patients progressed during the neoadjuvant period [10] . Early results from the first trials employing neoadjuvant immune-checkpoint blockade in patients with metastatic melanoma have shown higher rates of pCR (45%) in patients receiving combined ipilimumab/nivolumab compared with those who received nivolumab alone (25%), and combination therapy was associated with non-statistically significant improvements in progression-free, recurrence-free, and overall survival (OS) compared with single-agent nivolumab [11] . A prospective study of 10 patients with resectable stage III or oligometastatic stage IV melanoma treated with neoadjuvant combination ipilimumab/nivolumab showed similar rates of pCR (30%) and partial pathologic response (40%; pPR, 50% residual viable tumor). Those patients with either pCR or pPR have not recurred with a median follow up of over 24 months [12] . A prospective study of 27 patients with resectable stage III or oligometastatic stage IV melanoma treated with neoadjuvant pembrolizumab showed similar response rates; no patient with a pCR has recurred at a median follow up of over 18 months [13] .
The US Food and Drug Administration (FDA) issued the position statement: 'Pathologic complete response is defined as the absence of residual invasive cancer. . . after evaluation of the completely resected specimen including . . .all sampled regional lymph nodes following completion of neoadjuvant systemic therapy' [14] . The FDA additionally designated pCR as a surrogate end point to justify accelerated approval of a particular agent administered in the neoadjuvant (and adjuvant) setting for breast cancer [14, 15] . With growing application of neoadjuvant systemic therapy in patients with resectable metastatic melanoma, a critical challenge is therefore to establish uniform practices and widely-accepted criteria to determine the extent of pathologic response accurately and reproducibly. Here, we present standardized procedures for gross inspection and tissue submission and describe the continuum of histopathologic patterns of response observed following neoadjuvant-targeted therapy and immunotherapy. Consensus guidelines for recommended reporting parameters and scoring criteria are also presented.
Materials and methods
The International Neoadjuvant Melanoma Consortium meetings in 2016 and 2017 convened pathologists, oncologists, and surgeons from academic centers in multiple countries. Participants were invited by the Chairs of the group according to their experience with targeted and immune-checkpoint blockade therapy neoadjuvant trials in melanoma patients.
The pathology working group subsequently communicated in person, through teleconferences and written communications. This document represents the consensus opinion of its members and serves as an expanded companion to a broader effort summarizing the guidelines for principles of neoadjuvant treatment in melanoma (manuscript in preparation).
Results
Standardized procedures for pathologic assessment in the neoadjuvant setting Assessment of pretreatment biopsies. Pretreatment pathological confirmation of the diagnosis of metastatic melanoma is essential before initiating neoadjuvant therapy. This specimen often informs BRAF mutation status and/or the expression of immunoactive molecules (PD-L1) and may drive therapeutic selection [16] . It also enables morphologic and immunophenotypic tumor cell assessment and enables comparison with any residual tumor following therapy.
Clinical information provided to the pathologist with the surgical specimen. For proper specimen processing, the pathology team must be aware that it was procured following neoadjuvant systemic therapy. Information regarding the type and duration of neoadjuvant systemic therapy should be provided together with the number of radiographically positive nodes to direct processing.
Initial specimen handling. At present, most patients enrolled in neoadjuvant trials in melanoma have had surgically resectable nodal disease [9] [10] [11] 17] . Thus, only the approach to regional lymphadenectomy specimens will be discussed. Gross specimen photography is advised for mapping initial and potential subsequent tissue submission [18] . Sections submitted for histopathologic evaluation should include grossly obvious tumor as well as the entire pre-treatment biopsy site. Placement of a surgical clip during diagnostic biopsy can help direct subsequent localization of this site.
All lymph nodes (grossly positive and negative; Figure 1A and B) or tumor nodules (including necrotic or hemorrhagic areas) should be identified grossly and submitted for histopathologic assessment. Grossly matted nodes or extranodal spread should be documented. Three-dimensional measurements of the largest grossly positive node(s) should be provided. Further assessment is directed according to gross tumor size (see below). Of note, gross measurements may not correspond to viable tumor burden ( Figure 1A) ; thus, histopathologic measurements represent the gold standard for the determination of pathologic response.
Tissue submission for lymphadenectomy specimens with tumor burden 5 cm. Provided each lymph node grossly measures 5 cm in greatest dimension, each lymph node should be serially sectioned at $3-4 mm intervals and submitted entirely, ( Figure   1C , upper panel). Complete submission facilitates the most accurate assessment of residual viable tumor.
Tissue submission for lymphadenectomy specimens with tumor burden >5 cm. When the largest grossly positive lymph node exceeds 5 cm in greatest dimension, representative sections are considered sufficient. Specifically, sections representing one full slice (itself encompassing a complete cross section of the entire surface area), per 1 cm of each grossly involved lymph node are recommended ( Figure 1C , bottom panel). This approach mirrors that advocated by an international consortium of breast pathologists [18, 19] . Ultimately, the amount of tissue submitted for histopathologic evaluation should reflect an integrated assessment of the complete clinical, radiographic, and gross findings specific to a given case-particularly when there is evidence of grossly residual viable tumor [18] . Tissue procured from specimens resected after neoadjuvant therapy offer a critical resource for correlative studies determining pathways of response and/or resistance. While some studies (whole exome sequencing and T-cell receptor sequencing) may utilize FFPE, others (RNA sequencing and fresh tissue for cell dissociates) are ideally carried out on fresh or fresh frozen tissue. Institutions with tissue banking protocols are encouraged to develop policies for procurement of fresh tumor tissue, including areas of regression and viable tumor (if grossly evident). Verification of cellularity/viability with frozen section review of fresh tissue is encouraged. In rare cases, gross evidence of a tumor bed (treated or otherwise) is lacking in the surgical specimen. Placement of a surgical clip at the time of the diagnostic biopsy would be particularly useful in this situation to identify the tumor bed. Thorough sampling is advised to identify any residual or regressed tumor; it may be necessary to submit additional tissue depending on the findings of the initial histopathologic assessment.
Histopathologic assessment of the excised lymph nodes. In addition to standard AJCC staging parameters [4, 20] , evidence of therapy-specific effects should be described and quantified, including the relative percentage of tumor bed occupied by viable tumor, tumoral necrosis and/or melanosis, inflammatory infiltrate, and fibrosis (Table 1 ). These features are used to calculate the percent residual viable tumor:
% residual viable tumor ¼ surface area of residual viable tumor surface area of total assessed cross-sectional tumor bed :
The 'tumor bed' is defined as the area of the tissue occupied by viable tumor or tumoral regression (necrosis with or without clusters/sheets of pigmented macrophages and fibrosis/fibroinflammatory stroma). If multiple lymph nodes are/were involved by melanoma, the percent residual viable tumor should be calculated by summing the surface areas occupied by the multiple residual viable tumor deposits, and dividing that by the sum of the surface areas of the tumor beds in the histopathologically involved nodes.
Finally, routine application of immunohistochemistry (IHC) to identify/exclude viable tumor cells in neoadjuvant-treated specimens is not required. IHC should be applied based on a histopathologic suspicion for viable tumor, rather than as a reflex to secure the designation of pCR. When IHC is required, Sox-10 is recommended, since Sox-10 is a highly sensitive melanocytic antigen, and its nuclear localization renders it less susceptible to non-specific cytoplasmic staining caused by excessive pigmentation often encountered with Melan-A and HMB-45.
Defining pathologic response
A continuum of pathologic responses may be observed in patients treated with neoadjuvant-targeted or immune-checkpoint therapy. pCR is defined as the complete absence of residual viable tumor. In the early trials for patients with melanoma, pPR was empirically defined as 50% of the tumor bed occupied by viable tumor cells, and pathologic non-response (pNR) was defined as >50% of the tumor bed occupied by viable tumor cells [9, 21] . Some neoadjuvant immunotherapy studies have also utilized a category of 'near pCR/major PR' that was defined as >0% but 10% viable tumor cells [13, 22] . Newer grading systems supporting scoring of residual viable tumor as a continuous variable have also been proposed [22] . Long-term outcome studies are required to determine the extent to which pathologic response is associated with improved patient survival in distinct neoadjuvant settings.
Histopathologic patterns observed in melanoma specimens from patients treated with neoadjuvant BRAF/MEK inhibition
Two primary patterns were observed in patients with pCR in neoadjuvant-targeted therapy trials: (1) hyalinized fibrosis pattern (Figure 2A and B) and (2) tumoral melanosis pattern ( Figure 2C and D). A mixture of these patterns was also seen. The hyalinized fibrosis pattern consists of homogeneous pale eosinophilic collagen, effacing the lymph node architecture and replacing the previous metastatic deposit(s). The tumoral melanosis pattern of pCR is characterized by effacement of the lymph node by sheets of pigmented macrophages (melanophages). A variable extent of coagulative tumoral necrosis and fibrosis is usually associated with these melanophages.
Patterns of pPR and pNR include a continuum occupied by a variable density of viable tumor cells admixed with a similar spectrum of changes observed in pCR, including an admixture of tumoral necrosis and melanosis, lymphohistiocytic inflammation and/or fibrosis ( Figure 2E -J).
Histopathologic patterns observed in melanoma specimens from patients treated with neoadjuvant checkpoint inhibition
Specimens from patients receiving immune-checkpoint blockade demonstrated a response spectrum ranging from pCR to pNR ( Figure 3A-F) . Features of immune-mediated tumor regression were most often observed around the periphery of residual tumor, underscoring the importance of obtaining full crosssections of the tumor mass during grossing. Pathologic features of response include an immune infiltrate (moderate-high densities of tumor infiltrating lymphocytes, plasma cells, lymphoid aggregates and macrophages) together with features of wound healing/repair (immature, proliferative fibrosis and neovascularization) (supplementary Figures S1 and S2 , available at Annals of Oncology online). For the assessment of neoadjuvant immunecheckpoint blockade specimens, it remains to be determined whether additional studies, including assessments of CD3+ or CD8+ T-cell densities or an assessment of mutational load, might provide improved predictive value over routine histologic assessment.
Discussion
Here, we provide standardized procedures directing assessment of metastatic melanoma specimens and provide criteria to quantify the extent of pathologic response following neoadjuvant therapy. The premise of pCR as a surrogate end point is that the ability of a neoadjuvant therapy to eradicate tumor at local and regional sites correlates with eradication of distant micrometastatic disease and mirrors adjuvant therapy trials where impacts on survival (OS or DFS) are determined. However, such phase III adjuvant trials require significantly more time and patients to determine survival outcomes. The correlation between pCR and improved OS and/or DFS has been confirmed in neodjuvant trials for breast [23] , bladder [24] , rectal [25] , esophageal [26] , and gastric carcinomas [27] . In breast cancer, the extent of residual cancer following neoadjuvant therapy robustly predicts RFS • Less than 50% of the treated tumor bed is occupied by viable tumor cells. Note: percent tumor regression associated with improved patient outcomes for both targeted therapy and immunotherapy is an area of active investigation. Gross evaluation of the surgical specimen after neoadjuvant therapy • Three-dimensional macroscopic measurement of the largest grossly positive lymph node identified should be provided in the gross description.
• If the largest grossly positive lymph node measures £ 5 cm in greatest dimension:
• Each lymph node should be submitted entirely at 3-4 mm serially sectioned intervals ( Figure 1A ).
• For any grossly positive lymph node measuring > 5 cm in greatest dimension, representative sections of the largest lymph nodes may be utilized.
• For nodes >5 cm, sections representing a complete cross section of the entire surface area should be submitted per 1 cm of each grossly positive lymph node ( Figure 1B ).
• All lymph nodes <5 cm in specimens where the largest node(s) >5 cm should be submitted entirely ( Figure 1A ).
Microscopic templates:
( within phenotypic subsets and even within discrete stage categories [28] . However, while correlation between neoadjuvant pCR findings and adjuvant survival outcomes has not been absolute, preliminary data from neoadjuvant melanoma trials suggest a correlation of pCR with improved RFS among patients treated with neoadjuvant-targeted [29] and immune-checkpoint [13, 17, 21] therapies. Whether the survival correlates associated with pCR in targeted therapy are different from that seen with immune-checkpoint therapy requires further investigation. Specifically, either pCR or 'near pCR/major PR' (e.g. 10% viable tumor cells) may associate with improved survival indices in patients treated with neoadjuvant immune-checkpoint blockade.
In support of this concept, the Residual Cancer Burden (RCB) model largely confirms that pCR patients (RCB ¼ 0) have improved RFS compared with patients with non-pCR for neoadjuvant-treated breast cancer patients, particularly those with triple negative and Her2 positive tumours. However, in certain scenarios, patients with minimal viable tumor following neoadjuvant therapy (RCB-I) actually have better RFS than patients with pCR (RCB-0) [28] . This suggests either that residual tumor persists in occasional cases designated as pCR or that the difference between pCR and some minimal percentage of viable tumor may not be clinically significant. Furthermore, other organ systems, including lung and some early studies in melanoma, designate 'major pathologic response' to indicate 10% residual viable tumor [13, 17, 30] . In one melanoma study, patients with either a pCR or 10% residual viable tumor after neoadjuvant PD-1 blockade remained cancer free with a median follow up of 18 months [13] . It is therefore possible that the percentage of residual viable tumor following neoadjuvant therapy that correlates with improved melanoma survival may depend on the agent used. For this reason, we advocate recording the percentage residual viable tumor as a continuous variable until more definitive evidence becomes available.
Resection specimens from patients treated with immune-checkpoint blockade showed tumor beds that were more densely inflamed. In contrast, specimens from patients treated with targeted therapy were more often characterized by necrosis and hyalinized fibrosis. These differences likely reflect the varying mechanisms of drug action, but their clinical significance remains unclear. Additional studies in a larger number of patients correlating degree of pathologic response and individual histologic features with long-term outcomes will be required to establish an RCB model predictive of survival for each neoadjuvant therapy. The standardization of processing and reporting criteria as described herein maximizes our capacity to accomplish this goal, and is well suited for integration into future planned prognostic models that include patients treated in the neoadjuvant arena [4, 20] . 
